Prevention and treatment of chemotherapy-induced peripheral neuropathy

American Journal of Health-System Pharmacy

Volumn 71, Issue 1, 2014, Pages 19-25

  Piccolo, Jennifer ^a   Kolesar, Jill M ^b,c  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMIFOSTINE; AMITRIPTYLINE; BACLOFEN; CISPLATIN; DESIPRAMINE; DOCETAXEL; DULOXETINE; ERYTHROPOIETIN; FLUOROURACIL; FOLINIC ACID; GABAPENTIN; GLUCONATE CALCIUM; GLUTAMINE; GLUTATHIONE; KETAMINE; LEVACECARNINE; MAGNESIUM SULFATE; NORTRIPTYLINE; OXALIPLATIN; PACLITAXEL; PLACEBO; PREGABALIN; VENLAFAXINE; ANTIDEPRESSANT AGENT; ANTINEOPLASTIC AGENT; CALCIUM; MAGNESIUM; NEUROPROTECTIVE AGENT; NEUROTRANSMITTER UPTAKE INHIBITOR;

ADJUVANT THERAPY; ADVERSE OUTCOME; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY; HUMAN; MOTOR NEUROPATHY; NEUROPATHIC PAIN; NEUROTOXICITY; NONHUMAN; PAIN; PERIPHERAL NEUROPATHY; SENSORY NERVE CONDUCTION; SENSORY NEUROPATHY; CHEMICALLY INDUCED DISORDER; REVIEW;

ANTIDEPRESSIVE AGENTS; ANTINEOPLASTIC AGENTS; CALCIUM; HUMANS; MAGNESIUM; NEUROPROTECTIVE AGENTS; NEUROTRANSMITTER UPTAKE INHIBITORS; PERIPHERAL NERVOUS SYSTEM DISEASES;

EID: 84899139331     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp130126     Document Type: Article

References (38)

1. Stubblefield MD, Burstein HJ, Burton AW et al. NCCN task force: management of neuropathy in cancer. J Natl Compr Canc Netw. 2009; 7(suppl 5):S1-26.
2. Pachman DR, Barton DL, Watson JC et al. Chemotherapy-induced peripheral neuropathy: prevention and treatment. Clin Pharmacol Ther. 2011; 90:377-87.
3. Beijers AJ, Jongen JL, Vreugdenhil G. Chemotherapy-induced neurotoxicity: the value of neuroprotective strategies. Neth J Med. 2012; 70:18-25.
4. Kemp G, Rose P, Lurain J et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol. 1996; 14:2101-12.
5. Lorusso D, Ferrandina F, Freffi S et al. Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. Ann Oncol. 2003; 14:1086-93.
6. De Vos FY, Bos AM, Schaapveld M et al. A randomized phase II study of paclitaxel with carboplatin +/- amifostine as first line treatment in advanced ovarian carcinoma. Gynecol Oncol. 2005; 97:60-7.
7. Openshaw H, Beamon K, Synold TW et al. Neurophysiological study of peripheral neuropathy after high-dose paclitaxel: lack of neuroprotective effect of amifostine. Clin Cancer Res. 2004; 10:461-7.
8. Hilpert F, Stähle A, Tomé O et al. Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy - a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynäkologische Onkologoie (AGO) Ovarian Cancer Study Group. Support Cancer Care. 2005; 13:797-805.
9. Cascinu S, Catalano V, Cordella L et al. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2002; 20:3478-83.
10. 4adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity. Anticancer Drugs. 2009; 20:369-402.
11. Smyth JF, Bowman A, Perren T et al. Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomized trial. Ann Oncol. 1997; 96:4154-7.
12. Kottschasde LA, Sloan JA, Mazurczak MA et al. The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial. Support Cancer Care. 2011; 19:1769-77.
13. Bianchi R, Gilardini A, Rodriguez-Menendez V et al. Cisplatin-induced peripheral neuropathy: neuroprotection by erythropoietin without affecting tumour growth. Eur J Cancer. 2007; 43:710-7.
14. Cervellini I, Bello F, Frapolli R et al. The neuroprotective effect of erythropoietin in docetaxel-induced peripheral neuropathy causes no reduction of antitumor activity in 13,762 adenocarcinomabearing rats. Neurotox Res. 2010; 18:151- 60.
15. Grothey A, Hart LL, Rowland KM et al. Intermittent oxaliplatin administration and time-to-treatment-failure in metastatic colorectal cancer: final results of the Phase III CONcePT trial. http://meeting.ascopubs.org/cgi/content/abstract/26/15-suppl/4010 (accessed 2013 Sep 23).
16. Hochster HS, Grothey A, Childs BH. Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity. J Clin Oncol. 2007; 25:4028-9. Letter.
17. Gamelin L, Boisdron-Celle M, Morel A et al. Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusion and no impact on its efficacy. J Clin Oncol. 2008; 26:1188-90. Letter.
18. Grothey A, Nikcevich D, Sloan J et al. Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. J Clin Oncol. 2011; 29:421-7.
19. Wang WS, Lin JK, Lin TC et al. Oral glutamine is effective for preventing oxaliplatin- induced neuropathy in colorectal cancer patients. Oncologist. 2007; 12:312-9.
20. Loven D, Levavi H, Sabach G et al. Long-term glutamate supplementation failed to protect against peripheral neurotoxicity of paclitaxel. Eur J Cancer Care. 2009; 18:78-83.
21. Bianchi G, Vitali G, Caraceni A et al. Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine. Eur J Cancer. 2005; 41:1746-50.
22. Bellingham GA, Peng PW. Duloxetine: a review of its pharmacology and use in chronic pain management. Reg Anesth Pain Med. 2010; 35:294-303.
23. Durand JP, Deplanque G, Montheil V et al. Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized double-blind, placebo-controlled Phase III trial. Ann Oncol. 2012; 23:200-5.
24. Zafir A, Ara A, Banu N. In vivo antioxidant status: a putative target of antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry. 2009; 33:220-8.
25. Vadallouca A, Raptis E, Moka E et al. Pharmacological treatment of neuropathic cancer pain: a comprehensive review of the current literature. Pain Pract. 2011; 12:219-51.
26. Barton DL, Wos EJ, Qin R et al. A doubleblind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. Support Care Cancer. 2011; 19:833-41.
27. Kautio AL, Haanpää M, Saarto T et al. Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms. J Pain Symptom Manage. 2008; 35:31-9.
28. Kautio AL, Haanpää M, Leminen A et al. Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms. Anticancer Res. 2009; 29:2601-6.
29. Hammack J, Michalak J, Loprinzi C et al. Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy. Pain. 2002; 98:195-203.
30. Neurontin (gabapentin) package insert. New York: Pfizer; revised 2012 Dec.
31. Rao RD, Michalak JC, Sloan JA et al. Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer. 2007; 110:2110-8.
32. Lyrica (pregabalin) package insert. New York: Pfizer; revised 2012 Jun.
33. ClinicalTrials.gov. Prevention and treatment of chemotherapy-induced peripheral neuropathy in subjects with advanced colorectal cancer. http://clinicaltrials.gov/ct2/show/NCT00380874 (accessed 2013 Sep 26).
34. Lilly. FDA approves Cymbalta for treatment of generalized anxiety disorder. http://newsroom.lilly.com/releasedetail.cfm?releaseid=231196 (accessed 2013 Sep 26).
35. Lilly. FDA approves Cymbalta for the management of fibromyalgia. http://newsroom.lilly.com/releasedetail.cfm?releaseid=316740 (accessed 2013 Sep 26).
36. Yang Y, Lin J, Chen W et al. Duloxetine improves oxaliplatin-induced neuropathy in patients with colorectal cancer: an open-label pilot study. Support Cancer Care. 2012; 20:1491-7.
37. Matsuoka H, Makimura C, Koyama A et al. Pilot study of duloxetine for cancer patients with neuropathic pain non-responsive to pregabalin. Anticancer Res. 2012; 32:1805-10.
38. Smith EM, Pang H, Cirrincione C et al. Effect of duloxetine on pain function, and quality of life among patients with chemotherapy-induced peripheral neuropathy: a randomized clinical trial. JAMA. 2013; 309:1359-67.